SpringerLink
Log in

HIV and HCV: from Co-infection to epidemiology, transmission, pathogenesis, and treatment

  • Published:
Virologica Sinica

Abstract

Human immunodeficiency virus (HIV) is the infectious agent causing acquired immunodeficiency syndrome (AIDS), a deadliest scourge of human society. Hepatitis C virus (HCV) is a major causative agent of chronic liver disease and infects an estimated 170 million people worldwide, resulting in a serious public health burden. Due to shared routes of transmission, co-infection with HIV and HCV has become common among individuals who had high risks of blood exposures. Among hemophiliacs the co-infection rate accounts for 85%; while among injection drug users (IDU) the rate can be as high as 90%. HIV can accelerate the progression of HCV-related liver disease, particularly when immunodeficiency has developed. Although the effect of HCV on HIV infection is controversial, most studies showed an increase in mortality due to liver disease. HCV may act as a direct cofactor to fasten the progression of AIDS and decrease the tolerance of highly active antiretroviral therapy (HARRT). Conversely, HAART-related hepatotoxicity may enhance the progression of liver fibrosis. Due to above complications, co-infection with HCV and HIV-1 has imposed a critical challenge in the management of these patients. In this review, we focus on the epidemiology and transmission of HIV and HCV, the impact of the two viruses on each other, and their treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Reference

  1. Alter M J. 2002. Prevention of spread of hepatitis C. Hepatology, 36: S93–98.

    Article  PubMed  Google Scholar 

  2. Brandee L. 2003. Influence of maternal human immunodeficiency virus (HIV) co-infection on vertical transmission of hepatitis C virus (HCV): a meta-analysis. Int J Epidemiol, 32: 727–734.

    Article  Google Scholar 

  3. Brau N, Salvatore M, Rios-Bedoya C F, et al. 2006. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol, 44: 47–55.

    Article  PubMed  CAS  Google Scholar 

  4. Busch M P, Kleinman S H, Jackson B, et al. 2000. Nucleic acid amplification testing of blood donors for transfusion-transmitted infectious diseases: report of the Interorganizational Task Force on Nucleic Acid Amplification Testing of Blood Donors. Transfusion, 40: 143–159.

    Article  PubMed  CAS  Google Scholar 

  5. Busch M P. 2001. Closing the windows on viral transmission by blood transfusion. In: Blood safety in the new millennium (Stramer S L. ed.). AABB Press: Bethesda. p33–54.

    Google Scholar 

  6. Cardo D M, Culver D H, Ciesielski C A, et al. 1997. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. New Engl J Med, 337: 1485–1490.

    Article  PubMed  CAS  Google Scholar 

  7. Crespo M, Sauleda S, Esteban J I, et al. 2007. Peginterferon alpha-2b plus ribavirin vs interferon alpha-2b plus ribavirin for chronic hepatitis C in HIV-coinfected patients. J Viral Hepatitis, 14: 228–238.

    Article  CAS  Google Scholar 

  8. Daar E S, Lynn H, Donfield S, et al. 2001. Hepatitis C virus load is associated with human immunodeficiency virus type 1 disease progression in hemophiliacs. J Infect Dis, 183: 589–595.

    Article  PubMed  CAS  Google Scholar 

  9. Darby S C, Ewart D W, Giangrande P L, et al. 1997. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors’ Organisation. Lancet, 350: 1425–1431.

    Article  PubMed  CAS  Google Scholar 

  10. Di Bisceglie A M. 2000. Natural history of hepatitis C: its impact on clinical management. Hepatology, 31: 1014–1018.

    Article  PubMed  Google Scholar 

  11. Dimitrakopoulos A, Takou A, Haida A, et al. 2000. The prevalence of hepatitis B and C in HIV-positive Greek patients: relationship to survival of deceased AIDS patients. J Infection, 40: 127–131.

    Article  CAS  Google Scholar 

  12. Fainboim H, Gonzalez J, Fassio E, et al. 1999. Prevalence of hepatitis viruses in an anti-human immunodeficiency virus-positive population from Argentina. A multicentre study. J Viral Hepatitis, 6: 53–57.

    Article  CAS  Google Scholar 

  13. Fialaire P, Payan C, Vitour D, et al. 1999. Sustained disappearance of hepatitis C viremia in patients receiving protease inhibitor treatment for human immunodeficiency virus infection. J Infect Dis, 180: 574–575.

    Article  PubMed  CAS  Google Scholar 

  14. Gavazzi G, Richallet G, Morand P, et al. 1998. Effects of double and triple antiretroviral agents on the HCV viral load in patients coinfected with HIV and HCV. Patho Biol, 46: 412–415.

    CAS  Google Scholar 

  15. Giordano T P, Kramer J R, Souchek J, et al. 2004. Cirrhosis and hepatocellular carcinoma in HIV-infected veterans with and without the hepatitis C virus: a cohort study, 1992–2001. Arch Intern Med, 164: 2349–2354.

    Article  PubMed  Google Scholar 

  16. Greub G, Ledergerber B, Battegay M, et al. 2000. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet, 356: 1800–1805.

    Article  PubMed  CAS  Google Scholar 

  17. Hoffmann C, Rockstroh J, Kamps B S. 2005. HIV and HBV/HCV Coinfections, Paris, Cagliari, Wuppertal, Sevilla: Flying Publisher, 487.

    Google Scholar 

  18. Landesman S H, Kalish L A, Burns D N, et al. 1996. Obstetrical factors and the transmission of human immunodeficiency virus type 1 from mother to child. The Women and Infants Transmission Study. New Engl J Med, 334: 1617–1623.

    Article  PubMed  CAS  Google Scholar 

  19. Lauer G M, Nguyen T N, Day C L, et al. 2002. Human immunodeficiency virus type 1-hepatitis C virus coinfection: intraindividual comparison of cellular immune responses against two persistent viruses. J Virol, 76: 2817–2826.

    Article  PubMed  CAS  Google Scholar 

  20. Lesens O, Deschenes M, Steben M, et al. 1999. Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection. J Infect Dis, 179: 1254–1258.

    Article  PubMed  CAS  Google Scholar 

  21. Macias J, Castellano V, Merchante N, et al. 2004. Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine. AIDS, 18: 767–774.

    Article  PubMed  CAS  Google Scholar 

  22. Marcellin P, Boyer N, Gervais A, et al. 1997. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferonalpha therapy. Ann Intern Med, 127: 875–881.

    PubMed  CAS  Google Scholar 

  23. Matthews-Greer J M, Caldito G C, Adley S D, et al. 2001. Comparison of hepatitis C viral loads in patients with or without human immunodeficiency virus. Clin Diagn Lab Immun, 8: 690–694.

    Article  CAS  Google Scholar 

  24. Mauss S, Rockstroh J K. 2005. HCV/HIV-coinfection—is there a state of the art after APRICOT and RIBAVIC? J Antimicrob Chemoth, 56: 615–618.

    Article  CAS  Google Scholar 

  25. McHutchison J G, Gordon S C, Schiff E R, et al. 1998. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med, 339: 1485–1492.

    Article  PubMed  CAS  Google Scholar 

  26. Mohsen A H, Easterbrook P J, Taylor C, et al. 2003. Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients. Gut, 52: 1035–1040.

    Article  PubMed  CAS  Google Scholar 

  27. National Institutes of Health Consensus Development Conference Statement. 2002. Management of hepatitis C. Hepatology, 36(5 Suppl 1): S3–20.

    Google Scholar 

  28. Neau D, Trimoulet P, Winnock M, et al. 2001. Impact of protease inhibitors on intrahepatic hepatitis C virus viral load. AIDS, 15: 1736–1738.

    Article  PubMed  CAS  Google Scholar 

  29. Poynard T., Marcellin P., Lee S S, et al. 1998. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet, 352: 1426–1432.

    Article  PubMed  CAS  Google Scholar 

  30. Ragni M V, Bontempo F A. 1999. Increase in hepatitis C virus load in hemophiliacs during treatment with highly active antiretroviral therapy. J Infect Dis, 180: 2027–2029.

    Article  PubMed  CAS  Google Scholar 

  31. Rancinan C, Neau D, Saves M, et al. 2002. Is hepatitis C virus co-infection associated with survival in HIV-infected patients treated by combination antiretroviral therapy? AIDS, 16: 1357–1362.

    Article  PubMed  Google Scholar 

  32. Rutschmann O T., Negro F., Hirschel B, et al. 1998. Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremia in patients coinfected with HIV. J Infect Dis, 177: 783–785.

    Article  PubMed  CAS  Google Scholar 

  33. Sherman K E, Rouster S D, Chung R T, et al. 2002. Hepatitis C virus prevalence among patients coinfected with human immunodeficiency virus: a cross-sectional analysis of the U.S. adult AIDS clinical trials group. Clin Infect Dis, 34: 831–837.

    Article  PubMed  Google Scholar 

  34. Sherman M, Yoshida E M, Deschenes M, et al. 2006. Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitiss C patients who failed previous interferon therapy. Gut, 55:1631–1638.

    Article  PubMed  CAS  Google Scholar 

  35. Shiratori Y, Imazeki F, Moriyama M, et al. 2000. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med, 132: 517–524.

    PubMed  CAS  Google Scholar 

  36. Soriano V, Bravo R, García-Samaniego J, et al. 1997. Relapses of chronic hepatitis C in HIV-infected patients who responded to interferon therapy. Hepatitis/HIV Spanish Study Group. [Letter]. AIDS, 11: 400–401.

    PubMed  CAS  Google Scholar 

  37. Soto B, Rodrigo L, Garcia-Bengoechea M, et al. 1994. Heterosexual transmission of hepatitis C virus and the possible role of coexistent human immunodeficiency virus infection in the index case. A multicentre study of 423 pairings. J Intern Med, 236: 515–519.

    Article  PubMed  CAS  Google Scholar 

  38. Staples C T Jr, Rimland D, Dudas D. 1999. Hepatitis C in the HIV (human immuno-deficiency virus) Atlanta V. A. (Veterans Affairs Medical Center) Cohort Study (HAVACS): the effect of coinfection on survival. Clin Infect Dis, 29: 150–154.

    Article  PubMed  Google Scholar 

  39. Strasfeld L, Yungtai L O, Netski D, et al. 2003. The association of hepatitis C prevalence, activity, and genotype with HIV infection in a cohort of New York City drug users. JAIDS, 33: 356–364.

    PubMed  Google Scholar 

  40. Sulkowski M S, Moore R D, Mehta S H, et al. 2002. Hepatitis C and progression of HIV disease. JAMA, 288: 199–206.

    Article  PubMed  Google Scholar 

  41. Tedaldi E M, Baker R K, Moorman A C, et al. 2003. Influence of coinfection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy. Clin Infect Dis, 36: 363–367.

    Article  PubMed  Google Scholar 

  42. Tedaldi E M, Hullsiek K H, Malvestutto C D, et al. 2003. Prevalence and characteristics of hepatitis C virus coinfection in a human immunodeficiency virus clinical trials group: the Terry Beirn Community Programs for Clinical Research on AIDS. Clin Infect Dis, 36:1313–1317.

    Article  PubMed  Google Scholar 

  43. Tedeschi R, Pivetta E, Zanussi S, et al. 2003. Quantification of hepatitis C virus (HCV) in liver specimens and sera from patients with human immunodeficiency virus coinfection by using the versant HCV RNA 3.0 (Branched DNA-Based) DNA assay. J Clin Microbiol, 41: 3046–3050.

    Article  PubMed  Google Scholar 

  44. Thomas D L, Vlahov D, Solomon L, et al. 1995. Correlates of hepatitis C virus infections among injection drug users. Medicine, 74:212–220.

    Article  PubMed  CAS  Google Scholar 

  45. Thomas D L, Astemborski J, Rai R M, et al. 2000. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA, 284: 450–456.

    Article  PubMed  CAS  Google Scholar 

  46. Torre D, Tambini R, Cadario F, et al. 2001. Evolution of coinfection with human immuno-deficiency virus and hepatitis C virus in patients treated with highly active antiretroviral therapy. Clin Infect Dis, 33: 1579–1585.

    Article  PubMed  CAS  Google Scholar 

  47. Torriani F J, Soriano V. 2000. Chronic hepatitis C in HIVinfected individuals. AIDS Reviews, 2:168–177.

    Google Scholar 

  48. Trimoulet P, Neau D, Le Bail B, et al. 2002. Intrahepatic HCV RNA loads in 37 HIV-HCV co-infected patients with controlled HIV infection. J Med Virol, 67: 143–151.

    Article  PubMed  CAS  Google Scholar 

  49. Velati C, Romano L, Baruffi L, et al. 2002. Residual risk of transfusion-transmitted HCV and HIV infections by antibody-screened blood in Italy. Transfusion, 42:989–993.

    Article  PubMed  Google Scholar 

  50. Verma S, Wang C H, Govindarajan S, et al. 2006. Do type and duration of antiretroviral therapy attenuate liver fibrosis in HIV-hepatitis C viruscoinfected patients? Clin Infect Dis, 42: 262–270.

    Article  PubMed  CAS  Google Scholar 

  51. Wright T L, Hollander H, Pu X, et al. 1994. Hepatitis C in HIV infected patients with and without AIDS: prevalence and relationship to patient survival. Hepatology, 20: 1152–1155.

    PubMed  CAS  Google Scholar 

  52. Yee T T, Griffioen A, Sabin C A, et al. 2000. The natural history of HCV in a cohort of hemophilic patients infected between 1961 and 1985. Gut, 47: 845–851.

    Article  PubMed  CAS  Google Scholar 

  53. Yokozaki S, Takamatsu J, Nakano I, et al. 2000. Immunologic dynamics in hemophiliac patients infected with hepatitis C virus and human immunodeficiency virus: influence of antiretroviral therapy. Blood, 96: 4293–4299.

    PubMed  CAS  Google Scholar 

  54. Zhang C, Yang R, **a X, et al. 2002. High prevalence of HIV-1 and hepatitis C virus coinfection among injection drug users in the southeastern region of Yunnan, China. JAIDS, 29: 191–196.

    PubMed  Google Scholar 

  55. Zylberberg H, Benhamou Y, Lagneaux J L, et al. 2000. Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report. Gut, 47: 694–697.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan, 430072, China

    Lei Kang, **g Hu & Jian-guo Wu

  2. College of Life Sciences, Kunming University of Science and Technology, Kunming, 650224, China

    Xue-shan **a

Authors
  1. Lei Kang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. **g Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xue-shan **a
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jian-guo Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jian-guo Wu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kang, L., Hu, J., **a, Xs. et al. HIV and HCV: from Co-infection to epidemiology, transmission, pathogenesis, and treatment. Virol. Sin. 22, 443–450 (2007). https://doi.org/10.1007/s12250-007-0045-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12250-007-0045-9

Key words

CLC number

Search

Navigation